Search results
Results from the WOW.Com Content Network
Bedinvetmab, sold under the brand name Librela is a canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs. [ 3 ] [ 4 ] [ 5 ] Librela is sponsored by Zoetis. [ 5 ] [ 6 ]
In 2020, Zrielykh reported a high and statistically significant incidence of pancreatic cancer in Ukraine for a period of 10 year, there have been cases of morbidity also in children in 2013 compared with 2003. [19]
ovarian cancer, malignant ascites, gastric cancer cBR96-doxorubicin immunoconjugate: mab: humanized: Lewis-Y antigen: cancer Cedelizumab [47] mab: humanized: CD4: prevention of organ transplant rejections, treatment of autoimmune diseases Cemiplimab [32] Libtayo: mab: human: PD-1: Y: cutaneous squamous cell carcinoma Cergutuzumab amunaleukin ...
For premium support please call: 800-290-4726 more ways to reach us
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly ...
From 2005 to 2010, a hospital in Missouri overexposed 76 patients (most with brain cancer) during a five-year period because new radiation equipment had been set up incorrectly. [ 51 ] Although medical errors are exceptionally rare, radiation oncologists, medical physicists and other members of the radiation therapy treatment team are working ...
Relapse is a term to describe returning symptoms of the disease after a period of remission. In cancer-treatment, doctors usually avoid the term "cured" and instead prefer the term " no evidence of disease " ( NED ) to refer to a complete remission of cancer, which does not rule out the possibility of relapse.
Patients subsequently received an X-ray boost after completion of BNCT. The overall median survival time (MeST) was 27.1 months, and the 1 year and 2-year survival rates were 87.5 and 62.5%, respectively. Based on the reports of Miyatake, Kawabata, and Yamamoto, combining BNCT with an X-ray boost can produce a significant therapeutic gain.